Position in RZLT
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$0
+$0 QoQ
Shares Held
0
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2025
3 quarters on record
Derivatives in RZLT
reported options exposure · as of Mar 31, 2026CallValue
$1,180,960
CallShares
387,200
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Mar 31, 2026Centiva Capital, LP holds $38,119,877 across 36 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
14,610 | $11,288,270 | |
| 2 | ABVX |
Abivax S.A.
|
57,150 | $6,363,652 | |
| 3 | TERN |
Terns Pharmaceuticals, Inc.
|
101,225 | $5,336,582 | |
| 4 | SLNO |
Soleno Therapeutics Inc
|
101,234 | $3,389,314 | |
| 5 | MANE |
Veradermics, Inc
|
20,000 | $1,263,000 | |
| 6 | INBX |
Inhibrx Biosciences, Inc.
|
17,739 | $1,192,592 | |
| 7 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
2,147 | $958,721 | |
| 8 | CTMX |
CytomX Therapeutics, Inc.
|
200,000 | $940,000 |
All Filings in RZLT
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1,180,960 | 387,200 | Call | Sole | 2026-05-14 | |
| 2025-12-31 | $960,992 | 407,200 | Call | Sole | 2026-02-13 | |
| 2025-09-30 | $753,880 | 80,200 | Call | Sole | 2025-11-14 | |
| No filing history on record for this holder in this stock. | ||||||